Data / Drug companies / Cambrex Karlskoga AB
Cambrex Karlskoga AB: 13 products in the FDA NDC directory, labeler code 12651
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Cambrex Karlskoga AB (labeler code 12651) lists 13 products in the FDA National Drug Code Directory. By type: 13 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on August 5, 2026.
The request: Watch Cambrex Karlskoga AB (FDA labeler code 12651): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 12651
- Products in commercial distribution
- 13
- Packages
- 29
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- March 21, 1988
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 13 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 13 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 13 | 100% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Zongertinib | 12651-126 | Powder | Bulk ingredients | August 5, 2026 |
| Olanzapine | 12651-125 | Powder | Bulk ingredients | October 31, 2023 |
| Lidocaine | 12651-124 | Powder | Bulk ingredients | October 12, 2023 |
| Momelotinib dihydrochloride monohydrate | 12651-123 | Powder | Bulk ingredients | February 8, 2023 |
| Tesofensine/ns2330 citrate | 12651-121 | Powder | Bulk ingredients | January 19, 2021 |
| Berotralstat dihydrochloride | 12651-120 | Powder | Bulk ingredients | January 13, 2021 |
| 4-amiinobenzoic acid | 12651-119 | Powder | Bulk ingredients | March 5, 2020 |
| Rivastigmine | 12651-118 | Powder | Bulk ingredients | February 22, 2017 |
| Bupivacaine hydrochloride | 12651-111 | Powder | Bulk ingredients | July 19, 2016 |
| Bupivacaine base | 12651-116 | Powder | Bulk ingredients | August 1, 2011 |
| Lidocaine hydrochloride | 12651-113 | Powder | Bulk ingredients | June 30, 2006 |
| Benzoyl peroxide, hydrous | 12651-115 | Powder | Bulk ingredients | December 27, 2000 |
| Mesalamine | 12651-582 | Powder | Bulk ingredients | March 21, 1988 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.